Trial Profile
Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms TRIUMPH
- 13 Sep 2022 Results assessing diagnostic accuracy of Gene-Protein Assay to find HER2 intratumoral genetic and non-genetic heterogeneity using samples from this trial presented at the 47th European Society for Medical Oncology Congress
- 27 Jun 2022 Planned End Date changed from 31 Mar 2023 to 30 Apr 2022.
- 25 Jun 2021 Planned End Date changed from 31 Dec 2020 to 31 Mar 2023.